types of steroids

primobolan dosage

1_20_moh71zq3

Chlorambucil relates to aromatic derivatives of nitrogen mustard and acts as a bifunctional alkylating drug.Alkylation takes place through the formation of highly etilenimoniuma radicals. Probably, there is cross-linking radicals etilenimoniuma with the DNA helix and the subsequent violation of the DNA replication process. Pharmacokinetics The drug is well absorbed from the gastrointestinal tract. Chlorambucil is derived from blood plasma after an primobolan dosage average of 1.5 hours. It passes through the placental barrier.

Indications

  • Hodgkin’s disease (Hodgkin’s disease)
  • malignant lymphoma (including lymphosarcoma)
  • chronic lymphocytic leukemia
  • Waldenstrom’s macroglobulinemia

Contraindications : Hypersensitivity to any component of this medication; Pregnancy and lactation.

Precautions (necessary to compare the risks and benefits) – suppression of bone marrow function (expressed leukopenia, thrombocytopenia and anemia); Chickenpox (currently or recently transferred), herpes zoster, acute infectious disease of viral, fungal and bacterial origin, bone marrow infiltration by tumor cells, gout (in history), nefrourolitiaz urate, head injury (disorder), epilepsy (in history ), severe liver disease and kidney failure.

Dosing and Administration Leykeran usually is one of the components of the combination therapy, and therefore when choosing a dose and mode of administration should be referred to the literature. Leykeran ingested. Tablets should not be divided into parts. Hodgkin’s Disease in a monotherapy Leykeran usually used at a dose of 0.2 mg / kg of body weight per day for 4-8 weeks. Non-Hodgkin’s lymphoma in a monotherapy Leykeran usually used proviron initially in a dose of 0.1 – 0.2 mg / kg body weight per day for 4-8 weeks; then a supportive therapy or less daily dosage or intermittent rates. Chronic lymphocytic leukemia Starting Leykerana dose is 0.15 mg / kg body weight per day to as long as the total white blood cell count drops below 10,000 / ul. After 4 weeks after the first treatment course of therapy can be resumed at a maintenance dose of 0.1 mg / kg of body weight per day.Macroglobulinemia Waldenstrom Leykeran is the drug of choice. The initial dose is 6-12 mg / day every day, and after the development of leukopenia is recommended to move to maintenance therapy at a dose of 2 -8 mg / day every day for an indefinite period of time. Children: Leykeran be used to treat Hodgkin’s disease and non-Hodgkin’s lymphomas in children, using the same scheme as that of adults.When lymphocytic infiltration of the bone marrow or in the case of bone marrow hypoplasia Leykerana daily dose should not exceed 0.1 mg / kg body weight.

Side effect frequency Definition: very common (≥1 / 10), common (of ≥1 / 100 to ≤1 / 10), sometimes (from ≥1 / 1,000 to ≤1 / 100), rare (from ≥1 / 10,000 to ≤ . 1/1000), very rare (≤1 / 10,000) From the hematopoietic system: very often – leukopenia (reversible if the drug discontinued due time), thrombocytopenia, lymphopenia, neutropenia, decreased hemoglobin; rarely – irreversible inhibition of bone marrow function. On the part of the gastrointestinal tract: often – nausea, vomiting, diarrhea, ulceration of the oral mucosa; . rare – hepatotoxic effects of toxic and allergic genesis (gepatonekroz or cirrhosis, cholestasis, jaundice) The respiratory system: very rarely – interstitial pulmonary fibrosis (chronic administration of chlorambucil), interstitial pneumonia. Allergic reactions: sometimes – skin rash; rarely – urtikaropodobnaya rash, angioedema; rarely – exudative erythema multiforme (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell’s syndrome). From the nervous system: often – seizures in children with nephrotic syndrome; rare – local and / or generalized seizures in adults and children receiving chlorambucil in therapeutic doses or daily rates of high pulse therapy; rarely – uncertainty in walking, tremors, muscle twitches, peripheral neuropathy, paresis, agitation, confusion, severe weakness, anxiety, hallucinations. From the urinary system: rarely – aseptic cystitis. Other: drug hyperthermia, hyperuricemia or nephropathy due increased production of uric acid (the result of the rapid disintegration of the cells), irregular menstruation, secondary amenorrhea, azoospermia, secondary malignancy.

Overdose Symptoms: reversible pancytopenia, increased excitability, ataxia, recurrent epileptic seizures such as grand mal. A specific antidote is not known. Therapeutic measures: immediate gastric lavage, monitoring and maintenance of vital functions of the body, careful monitoring of blood tests and general supportive measures, including transfusion of blood or blood components may be needed.Dialysis is not effective.

Interaction with other medicinal products In an application with drugs, oppressive blood, may increase the myelotoxicity. In an application with protivopodagricakih funds required adjustment last dose (chlorambucil may increase the concentration of uric acid in the blood). Tricyclic antidepressants, as well as haloperidol, maprotiline, monoamine oxidase inhibitors, phenothiazines, thioxanthenes may reduce the threshold for seizure activity and increase the risk of seizures. Drugs that bind extensively to plasma proteins, increase chlorambucil toxicity (competition in the communication level with the protein). with the inactivated viral vaccines – reduction of the production of antibodies in response to vaccines; with live virus vaccines – intensification of replication of vaccine virus, increasing its side / adverse effects and / or reduce antibody production.

Leykeran is a cytotoxic agent which should only be used under the supervision of a physician who is experienced in the use of these drugs. When intact outer shell contact primobolan dosage tablets harmless skin.Dividing tablets prohibited. When using Leykerana tablets should follow the recommendations on the use of cytotoxic drugs. Since Leykeran can cause irreversible inhibition of bone marrow function, during treatment should be systematically (at least 2-3 times per week) to make a complete blood count with peripheral blood formed elements. When used in therapeutic doses it inhibits the production Leykeran lymphocytes and to a lesser extent affect the number of neutrophils and platelets, and hemoglobin level. No need to stop taking Leykerana the first signs of reducing the number of neutrophils, but it should be remembered that the reduction in the number of neutrophils can last for 10 or more days after the last dose. Patients previously lechivshimsya tsitostatacheskimi drugs or undergo radiation therapy, Leykeran administered no earlier than in 1.5-2 months after the previous treatment, in the absence of severe leukopenia, thrombocytopenia and anemia. Children with nephrotic syndrome, patients receiving high-dose pulse therapy leukeran, as well as patients with a history of seizures should be under close medical supervision during treatment leukeran because they have the risk of seizures may be increased.Patients with impaired renal excretory function should be monitored carefully, because they may develop a more severe myelosuppression associated with azotemia. When the concentration of uric acid in the blood serum is recommended that the use of funds, basified urine. The development of kidney disease can be prevented by adequate fluid intake, or the appointment of allopurinol if necessary. Patients with severe hepatic impairment should be given lower doses. Since the use of alkilirukntsih funds associated with a significant increase in the incidence of acute leukemia, the appointment of chlorambucil is necessary to compare the risk of acute leukemia with a potential therapeutic effect of the drug. Patients of childbearing age should use reliable methods of contraception.

Cautions Leykeran is a cytotoxic agent which should only be used under the supervision of a physician who is experienced in the use of these drugs. When intact outer shell contact Leykerana tablets harmless skin.Dividing tablets prohibited. When using Leykerana tablets should follow the recommendations on the use of cytotoxic drugs. Since Leykeran can cause irreversible inhibition of primobolan dosage bone marrow function, during treatment should be systematically (at least 2-3 times per week) to make a complete blood count with peripheral blood formed elements. When used in therapeutic doses Leykeran inhibits the production of lymphocytes and to a lesser extent, affects the number of neutrophils and platelets, as well as the level of hemoglobin. No need to stop taking Leykerana the first signs of reducing the number of neutrophils, but it should be remembered that the reduction in the number of neutrophils may continue for 10 or more days after the last dose. Patients previously lechivshimsya tsitostatacheskimi drugs or undergo radiation therapy, Leykeran administered no earlier than in 1.5-2 months after the previous treatment, in the absence of severe leukopenia, thrombocytopenia and anemia. Children with nephrotic syndrome, patients receiving high-puls- leukeran therapy, and patients with a history of seizures should be under close medical supervision during treatment leukeran because they have the risk of seizures may be increased. Patients with impaired renal excretory function should be monitored carefully, because they may develop a more severe myelosuppression associated with azotemia. When the concentration of uric acid in the blood serum is recommended that the use of funds, basified urine. The development of kidney disease can be prevented by adequate fluid intake, or the appointment of allopurinol if necessary. Patients with severe hepatic impairment should be given lower doses. Since the use of alkilirukntsih funds associated with a significant increase in the incidence of acute leukemia, the appointment of chlorambucil is necessary to compare the risk of acute leukemia with a potential therapeutic effect of the drug. Patients of childbearing age should use reliable methods of contraception. tri tren healthy food for bodybuilding steroids charts vegan bodybuilding diet